昊海生物科技(06826.HK)擬收購廈門南鵬光學51%股權
格隆匯12月2日丨昊海生物科技(06826.HK)發佈公吿,2021年12月1日,受讓方(上海昊海醫藥科技發展有限公司,公司全資附屬公司)、轉讓方(廈門南鵬集團有限公司及李志毅女士)與原代理經銷權持有人(即南鵬集團有限公司)簽訂股權轉讓協議,據此,公司同意收購廈門南鵬光學有限公司合計51%股權;及原代理經銷權持有人同意,放棄其於原代理經銷權協議的權利並透過促使亨泰光學與南鵬亨泰簽訂新代理經銷權協議,將相關權利轉讓予南鵬亨泰,總對價為人民幣7000萬元。
收購事項完成後,目標公司將由受讓方、轉讓方甲及轉讓方乙分別擁有51%、40%及9%股權。目標集團主要從事硬性角膜接觸鏡(“RGP”)及角膜塑形鏡產品的銷售。自2015年10月起,目標集團享有亨泰光學供應的目標產品於中國的獨家代理經銷權。
公吿表示,為進一步豐富集團於近視防控領域的產品佈局,鞏固並提升集團眼科業務的競爭力,2021年3月,集團收購了上海亨泰視覺科技有限公司55%股權,同時,取得亨泰光學部分角膜塑形鏡產品(“邁兒康myOK”品牌)及兒童近視管控光學鏡產品於中國的獨家代理經銷權。自2015年10月起,目標集團享有亨泰光學供應的部分角膜塑形鏡產品(“Hiline”品牌)於中國的獨家代理經銷權。
收購目標集團將有助集團取得亨泰光學於中國供應的所有產品的獨家代理經銷權,豐富眼科產品組合,快速提升其於近視防控領域的產品及銷售佈局。待收購事項完成後,集團與目標集團期望於品牌推廣、市場推廣活動、銷售管道及資源共用等方面產生協同效應,擴大集團角膜塑形鏡產品的市場份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.